Regeneron Strikes Deal With Genentech To Market Eylea

Law360, New York (January 3, 2012, 2:19 PM EST) -- Regeneron Pharmaceuticals Inc. has partially settled its patent litigation in New York against Genentech Inc., securing a licensing agreement in order to market Eylea, a treatment for macular degeneration, the company announced Tuesday.

Under the nonexclusive licensing agreement, Regeneron agreed to pay Roche Group unit Genentech $60 million until May 2016 if sales of Regeneron’s Eylea reached $400 million. Additionally, Regeneron said it had agreed to pay almost 5 percent in royalties if U.S. sales of Eylea were $400 million to $3 billion.

If U.S. sales...
To view the full article, register now.